The $100 Trillion Shift from Sick Care to Health Care

Modern medicine is a $5.3 trillion industry built on a single premise:

Wait until you're broken. Then fix you.

Think about your last interaction with the healthcare system. Chances are, something was already wrong. You had symptoms. Pain. A lump. Abnormal lab results. You went to the doctor because you were sick.

This is "sick care"--a reactive system designed to treat disease after it manifests. And it's extraordinarily good at what it does. We can replace hearts, target tumors with millimeter precision, and keep people alive through conditions that were death sentences a generation ago.

But here's the thing: fixing broken things is expensive. And no matter how good we get at treatment, we'll never outrun the fundamental math of chronic disease.

So what if we flipped the entire model?

What if the biggest healthcare companies of 2040 are ones that ensure you never become a patient in the first place?

The Preventive Moat

Here's a simple business observation with profound implications:

Treatment is episodic. Prevention is recurring.

When you treat a disease, you have a customer for the duration of their illness. Maybe months. Maybe years for chronic conditions. But the relationship has an endpoint.

Prevention is different. If your product keeps someone healthy, they use it for life. The CAC-to-LTV math becomes absurd when your total addressable market is "everyone who doesn't want to get sick" and your retention period is "decades."

This is why we think prevention is the ultimate moat in healthcare.

The incumbents--pharmaceutical companies, hospital systems, insurance giants--are all optimized for sick care. Their revenue models depend on disease. A true prevention-first company isn't competing with them. It's building a parallel system--one where the goal is keeping people out of the traditional healthcare system entirely.

Diagnostics Are the Wedge

If prevention is the destination, diagnostics are the road.

You can't prevent what you can't measure. And historically, measurement has been expensive, invasive, and episodic--annual checkups, blood draws, imaging studies. By the time you detect most conditions, they've been developing for years.

But that's changing. Fast.

Continuous glucose monitors (CGMs) went from diabetes management tools to consumer wellness devices. Companies like Levels showed that non-diabetics could gain insights from tracking their glucose in real-time, sparking a broader movement toward metabolic health optimization.

Wearables have moved beyond step counting. The Apple Watch can detect atrial fibrillation--the FDA qualified its AFib History feature as a Medical Device Development Tool in May 2024. Oura and Whoop track recovery, sleep quality, and readiness, turning biometric data into actionable health insights.

Liquid biopsy companies like GRAIL are detecting cancer from blood draws, catching disease at Stage 1 instead of Stage 4. Their Galleri test can screen for a fingerprint of over 50 cancers before symptoms appear, with over 250,000 tests sold in the U.S. alone.

The pattern: cheap, continuous sensing creates data that enables intervention before symptoms appear. The diagnostic isn't just a tool--in many cases, the diagnostic IS the drug.

Healthspan, Not Lifespan

When most people hear "longevity," they imagine mad scientists trying to help billionaires live to 150. Cryonics. Blood transfusions from teenagers. It sounds like science fiction.

But that's not what excites us.

What excites us is healthspan--the number of healthy years you have, not just the total number of years.

Here's a stat that should haunt everyone: the average American spends their last 12.4 years in poor health. According to a 2024 Mayo Clinic study published in JAMA Network Open, the United States has the largest "healthspan-lifespan gap" of any country surveyed--meaning Americans spend more years burdened by chronic disease and disability than any other developed nation. This gap has grown 13% over the past two decades, driven primarily by the rise in noncommunicable diseases.

Compressing morbidity--the period of decline before death--is the real prize. It's not about adding years to life; it's about adding life to years.

The Investment Thesis

What are we looking for?

Teams working upstream. We want to back companies that catch disease at Stage 0, not Stage 4. Prevention compounds; treatment doesn't.

Continuous over episodic. If your product requires an annual visit or a one-time test, you're building in sick care's image. We want products that live with the patient.

Data as moat. The best preventive health companies will accumulate longitudinal data on millions of people--data that enables better predictions and more personalized interventions.

Consumer-grade experience, clinical-grade rigor. Prevention only works if people actually use the tools. That means great UX, not just great science.

The transition from sick care to health care is a massive opportunity. The global preventive healthcare market is projected to grow from $296 billion in 2024 to $1.19 trillion by 2034--and that's just the technologies and services layer, not the broader economic impact of keeping people healthier longer. The companies that lead this transition don't exist yet.

But they will. And we want to find them first.

ADIN is an AI-powered venture network backing the future of technology. If you're building in preventive health, diagnostics, or longevity, we want to hear from you.